BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16435599)

  • 1. [Treatment with statins in general medicine: dosage and effectiveness. Results of the observational study STATIMED].
    Amouyel P; Lamarque H; Gayet JL
    Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1206-11. PubMed ID: 16435599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates.
    Baessler A; Fischer M; Huf V; Mell S; Hengstenberg C; Mayer B; Holmer S; Riegger G; Schunkert H
    Int J Cardiol; 2005 May; 101(2):293-8. PubMed ID: 15882678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation).
    Assmann G; Benecke H; Neiss A; Cullen P; Schulte H; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):776-83. PubMed ID: 17001218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of medical guidelines for the prescription of statins].
    Chevalier C; Giral P; Chinaud F; Carzon M; Gartenlaub D; Blanchon B; Trutt B
    Rev Epidemiol Sante Publique; 2002 Oct; 50(5):463-73. PubMed ID: 12471339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO).
    Bourgault C; Davignon J; Fodor G; Gagné C; Gaudet D; Genest J; Lavoie MA; Leiter L; McPherson R; Sénécal M; Marentette M; Sebaldt RJ
    Can J Cardiol; 2005 Nov; 21(13):1187-93. PubMed ID: 16308595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results.
    Heintjes EM; Hirsch MW; van der Linden MW; O'Donnell JC; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2008 Aug; 24(8):2241-50. PubMed ID: 18578957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD; Kleit AN; Nietert PJ; Ornstein S
    Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.